1 1470 138 DISTINCT GENE EXPRESSION PROFILES IN IMMORTALIZED HUMAN UROTHELIAL CELLS EXPOSED TO INORGANIC ARSENITE AND ITS METHYLATED TRIVALENT METABOLITES. INORGANIC ARSENIC IS AN ENVIRONMENTAL CARCINOGEN. THE GENERATION OF TOXIC TRIVALENT METHYLATED METABOLITES COMPLICATES THE STUDY OF ARSENIC-MEDIATED CARCINOGENESIS. THIS STUDY SYSTEMATICALLY EVALUATED THE EFFECT OF CHRONIC TREATMENT WITH SODIUM ARSENITE (IAS(III)), MONOMETHYLARSONOUS ACID (MMA(III)), AND DIMETHYLARSINOUS ACID (DMA(III)) ON IMMORTALIZED HUMAN UROEPITHELIAL CELLS (SV-HUC-1 CELLS) USING CDNA MICROARRAY. AFTER EXPOSURE FOR 25 PASSAGES TO IAS(III) (0.5 MICROM), MMA(III) (0.05, 0.1, OR 0.2 MICROM), OR DMA(III) (0.2 OR 0.5 MICROM), SIGNIFICANT COMPOUND-SPECIFIC MORPHOLOGIC CHANGES WERE OBSERVED. A SET OF 114 GENES (5.7% OF THE EXAMINED GENES) WAS DIFFERENTIALLY EXPRESSED IN ONE OR MORE SETS OF ARSENICAL-TREATED CELLS COMPARED WITH UNTREATED CONTROLS. EXPRESSION ANALYSIS SHOWED THAT EXPOSURE OF CELLS TO DMA(III) RESULTED IN A GENE PROFILE DIFFERENT FROM THAT IN CELLS EXPOSED TO IAS(III) OR MMA(III), AND THAT THE IAS(III)-INDUCED GENE PROFILE WAS CLOSEST TO THAT IN THE TUMORIGENIC HUC-1-DERIVED 3-METHYLCHOLANTHRENE-INDUCED TUMORIGENIC CELL LINE MC-SV-HUC T2, WHICH WAS DERIVED FROM SV-HUC-1 CELLS BY METHYLCHOLANTHRENE TREATMENT. OF THE GENES AFFECTED BY ALL THREE ARSENICALS, ONLY ONE, THAT CODING FOR INTERLEUKIN-1 RECEPTOR, TYPE II, SHOWED ENHANCED EXPRESSION, A FINDING CONFIRMED BY THE REDUCED INCREASE IN NF-KAPPAB (NUCLEAR FACTOR KAPPA B) ACTIVITY SEEN IN RESPONSE TO INTERLEUKIN-1BETA IN IAS(III)-EXPOSED CELLS. THE EXPRESSION OF 11 GENES WAS SUPPRESSED BY ALL THREE ARSENICALS. 5-AZA-DEOXYCYTIDINE PARTIALLY RESTORED THE TRANSCRIPTION OF SEVERAL SUPPRESSED GENES, SHOWING THAT EPIGENETIC DNA METHYLATION WAS PROBABLY INVOLVED IN ARSENICAL-INDUCED GENE REPRESSION. OUR DATA DEMONSTRATE THAT CHRONIC EXPOSURE TO IAS(III), MMA(III), OR DMA(III) HAS DIFFERENT EPIGENETIC EFFECTS ON UROTHELIAL CELLS AND REPRESSES NF-KAPPAB ACTIVITY. 2006 2 473 35 ARSENIC AND URINARY BLADDER CELL PROLIFERATION. EPIDEMIOLOGIC STUDIES HAVE DEMONSTRATED THAT A CLOSE ASSOCIATION EXISTS BETWEEN THE ELEVATED LEVELS OF ARSENIC IN DRINKING WATER AND THE INCIDENCE OF CERTAIN CANCERS, INCLUDING TRANSITIONAL CELL CARCINOMAS OF THE URINARY BLADDER. WE HAVE EMPLOYED IN VITRO AND IN VIVO MODELS TO EXAMINE THE EFFECTS OF SODIUM ARSENITE ON THE URINARY BLADDER EPITHELIUM. MICE EXPOSED TO 0.01% SODIUM ARSENITE IN DRINKING WATER DEMONSTRATED HYPERPROLIFERATION OF THE BLADDER UROEPITHELIUM WITHIN 4 WEEKS AFTER INITIATING TREATMENT. THIS OCCURRED IN THE ABSENCE OF AMORPHOUS PRECIPITATES AND WAS ACCOMPANIED BY THE ACCUMULATION OF TRIVALENT ARSENITE (IAS(3+)), AND TO A LESSER EXTENT DIMETHYLARSENIC (DMA), ARSENATE (IAS(5+)), AND MONOMETHYLARSENIC (MMA) IN BLADDER TISSUE. IN CONTRAST TO THE BLADDER, URINARY SECRETION WAS PRIMARILY IN THE FORM OF DMA AND MMA. ARSENIC-INDUCED CELL PROLIFERATION IN THE BLADDER EPITHELIUM WAS CORRELATED WITH ACTIVATION OF THE MAP KINASE PATHWAY, LEADING TO EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) KINASE ACTIVITY, AP-1 ACTIVATION, AND EXPRESSION OF AP-1-ASSOCIATED GENES INVOLVED IN CELL PROLIFERATION. ACTIVATION OF THE MAP KINASE PATHWAY INVOLVED BOTH EPIDERMAL GROWTH FACTOR (EGF) RECEPTOR-DEPENDENT AND -INDEPENDENT EVENTS, THE LATTER INVOLVING SRC ACTIVATION. STUDIES SUMMARIZED IN THIS REVIEW SUGGEST THAT ARSENIC ACCUMULATES IN URINARY BLADDER EPITHELIUM CAUSING ACTIVATION OF SPECIFIC SIGNALING PATHWAYS THAT LEAD TO CHRONIC INCREASED CELL PROLIFERATION. THIS MAY PLAY A NON-EPIGENETIC ROLE IN CARCINOGENESIS BY INCREASING THE PROLIFERATION OF INITIATED CELLS OR INCREASING THE MUTATIONAL RATE. 2004 3 482 30 ARSENITE BINDS TO THE ZINC FINGER MOTIF OF TIP60 HISTONE ACETYLTRANSFERASE AND INDUCES ITS DEGRADATION VIA THE 26S PROTEASOME. ARSENIC IS A UBIQUITOUS ENVIRONMENTAL CONTAMINANT WITH WIDESPREAD PUBLIC HEALTH CONCERN. EPIDEMIOLOGICAL STUDIES HAVE REVEALED THAT CHRONIC HUMAN EXPOSURE TO ARSENIC IN DRINKING WATER IS ASSOCIATED WITH THE PREVALENCE OF SKIN, LUNG, AND BLADDER CANCERS. ABERRANT HISTONE MODIFICATIONS (E.G., METHYLATION, ACETYLATION, AND UBIQUITINATION) WERE PREVIOUSLY FOUND TO BE ACCOMPANIED BY ARSENIC EXPOSURE; THUS, PERTURBATION OF EPIGENETIC PATHWAYS IS THOUGHT TO CONTRIBUTE TO ARSENIC CARCINOGENESIS. ARSENITE IS KNOWN TO INTERACT WITH ZINC FINGER MOTIFS OF PROTEINS, AND ZINC FINGER MOTIF IS PRESENT IN AND INDISPENSABLE FOR THE ENZYMATIC ACTIVITIES OF CRUCIAL HISTONE-MODIFYING ENZYMES ESPECIALLY THE MYST FAMILY OF HISTONE ACETYLTRANSFERASES (E.G., TIP60). HENCE, WE REASONED THAT TRIVALENT ARSENIC MAY TARGET THE ZINC FINGER MOTIF OF THESE ENZYMES, DISTURB THEIR ENZYMATIC ACTIVITIES, AND ALTER HISTONE ACETYLATION. HEREIN, WE FOUND THAT AS(3+) COULD BIND DIRECTLY TO THE ZINC-FINGER MOTIF OF TIP60 IN VITRO AND IN CELLS. IN ADDITION, EXPOSURE TO AS(3+) COULD LEAD TO A DOSE-DEPENDENT DECREASE IN TIP60 PROTEIN LEVEL VIA THE UBIQUITIN-PROTEASOME PATHWAY. THUS, THE RESULTS FROM THE PRESENT STUDY REVEALED, FOR THE FIRST TIME, THAT ARSENITE MAY TARGET CYSTEINE RESIDUES IN THE ZINC-FINGER MOTIF OF THE TIP60 HISTONE ACETYLTRANSFERASE, THEREBY ALTERING THE H4K16AC HISTONE EPIGENETIC MARK. OUR RESULTS ALSO SHED SOME NEW LIGHT ON THE MECHANISMS UNDERLYING THE ARSENIC-INDUCED EPIGENOTOXICITY AND CARCINOGENESIS IN HUMANS. 2017 4 192 40 ACETYLATED H4K16 BY MYST1 PROTECTS UROTSA CELLS FROM ARSENIC TOXICITY AND IS DECREASED FOLLOWING CHRONIC ARSENIC EXPOSURE. ARSENIC, A HUMAN CARCINOGEN THAT IS ASSOCIATED WITH AN INCREASED RISK OF BLADDER CANCER, IS COMMONLY FOUND IN DRINKING WATER. AN IMPORTANT MECHANISM BY WHICH ARSENIC IS THOUGHT TO BE CARCINOGENIC IS THROUGH THE INDUCTION OF EPIGENETIC CHANGES THAT LEAD TO ABERRANT GENE EXPRESSION. PREVIOUSLY, WE REPORTED THAT THE SAS2 GENE IS REQUIRED FOR OPTIMAL GROWTH OF YEAST IN THE PRESENCE OF ARSENITE (AS(III)). YEAST SAS2P IS ORTHOLOGOUS TO HUMAN MYST1, A HISTONE 4 LYSINE 16 (H4K16) ACETYLTRANSFERASE. HERE, WE SHOW THAT H4K16 ACETYLATION IS NECESSARY FOR THE RESISTANCE OF YEAST TO AS(III) THROUGH THE MODULATION OF CHROMATIN STATE. WE FURTHER EXPLORED THE ROLE OF MYST1 AND H4K16 ACETYLATION IN ARSENIC TOXICITY AND CARCINOGENESIS IN HUMAN BLADDER EPITHELIAL CELLS. THE EXPRESSION OF MYST1 WAS KNOCKED DOWN IN UROTSA CELLS, A MODEL OF BLADDER EPITHELIUM THAT HAS BEEN USED TO STUDY ARSENIC-INDUCED CARCINOGENESIS. SILENCING OF MYST1 REDUCED ACETYLATION OF H4K16 AND INDUCED SENSITIVITY TO AS(III) AND TO ITS MORE TOXIC METABOLITE MONOMETHYLARSONOUS ACID (MMA(III)) AT DOSES RELEVANT TO HIGH ENVIRONMENTAL HUMAN EXPOSURES. IN ADDITION, BOTH AS(III) AND MMA(III) TREATMENTS DECREASED GLOBAL H4K16 ACETYLATION LEVELS IN A DOSE- AND TIME-DEPENDENT MANNER. THIS INDICATES THAT ACETYLATED H4K16 IS REQUIRED FOR RESISTANCE TO ARSENIC AND THAT A REDUCTION IN ITS LEVELS AS A CONSEQUENCE OF ARSENIC EXPOSURE MAY CONTRIBUTE TO TOXICITY IN UROTSA CELLS. BASED ON THESE FINDINGS, WE PROPOSE A NOVEL ROLE FOR THE MYST1 GENE IN HUMAN SENSITIVITY TO ARSENIC. 2009 5 6663 37 UPREGULATION OF HISTONE-LYSINE METHYLTRANSFERASES PLAYS A CAUSAL ROLE IN HEXAVALENT CHROMIUM-INDUCED CANCER STEM CELL-LIKE PROPERTY AND CELL TRANSFORMATION. WHILE HEXAVALENT CHROMIUM [CR(VI)] IS GENERALLY CONSIDERED AS A GENOTOXIC ENVIRONMENTAL CARCINOGEN, STUDIES SHOWED THAT CR(VI) EXPOSURE ALSO CAUSES EPIGENETIC CHANGES. HOWEVER, WHETHER CR(VI)-CAUSED EPIGENETIC DYSREGULATIONS PLAYS AN IMPORTANT ROLE IN CR(VI) CARCINOGENICITY REMAIN LARGELY UNKNOWN. THE AIM OF THIS STUDY WAS TO DETERMINE IF CHRONIC LOW DOSE CR(VI) EXPOSURE CAUSES EPIGENETIC CHANGES, THE UNDERLYING MECHANISM AND WHETHER CHRONIC LOW DOSE CR(VI) EXPOSURE-CAUSED EPIGENETIC DYSREGULATION CONTRIBUTES CAUSALLY TO CR(VI)-INDUCED CANCER STEM CELL (CSC)-LIKE PROPERTY AND CELL TRANSFORMATION. TWO IMMORTALIZED HUMAN BRONCHIAL EPITHELIAL CELL LINES (BEAS-2B AND 16HBE) WERE EXPOSED TO 0.25 MUM OF K(2)CR(2)O(7) FOR 20 AND 40 WEEKS TO INDUCE CELL TRANSFORMATION, RESPECTIVELY. CR(VI)-INDUCED EPIGENETIC CHANGES WERE EXAMINED IN CR(VI)-TRANSFORMED CELLS AND CR(VI) EXPOSURE-CAUSED HUMAN LUNG CANCER TISSUES. PHARMACOLOGICAL INHIBITORS AND GENE KNOCKDOWN EXPERIMENTS WERE USED TO DETERMINE THE ROLE OF EPIGENETIC DYSREGULATION IN CR(VI) CARCINOGENICITY. WE FOUND THAT CHRONIC CR(VI) EXPOSURE CAUSES EPIGENETIC DYSREGULATION AS EVIDENCED BY THE INCREASED LEVELS OF HISTONE H3 REPRESSIVE METHYLATION MARKS (H3K9ME2 AND H3K27ME3) AND THE RELATED HISTONE-LYSING METHYLTRANSFERASES (HMTASES). PHARMACOLOGICAL INHIBITION OR KNOCKDOWN OF HMTASES REDUCES H3 REPRESSIVE METHYLATION MARKS AND MALIGNANT PHENOTYPES OF CR(VI)-TRANSFORMED CELLS. MOREOVER, KNOCKDOWN OF HMTASES IN PARENTAL CELLS SIGNIFICANTLY REDUCES CHRONIC CR(VI) EXPOSURE-INDUCED CSC-LIKE PROPERTY AND CELL TRANSFORMATION. FURTHER MECHANISTIC STUDY REVEALED THAT KNOCKDOWN OF HMTASES DECREASES CR(VI) EXPOSURE-CAUSED DNA DAMAGE. OUR FINDINGS INDICATE THAT CHRONIC CR(VI) EXPOSURE INCREASES H3 REPRESSIVE METHYLATION MARKS BY INCREASING THE RELATED HMTASES EXPRESSION; AND THAT INCREASED EXPRESSION OF HMTASES PLAYS A CAUSAL ROLE IN CR(VI)-INDUCED CSC-LIKE PROPERTY AND CELL TRANSFORMATION. 2018 6 2099 38 EPIGENETIC EFFECTS OF LOW-LEVEL SODIUM ARSENITE EXPOSURE ON HUMAN LIVER HEPARG CELLS. CHRONIC EXPOSURE TO INORGANIC ARSENIC IS ASSOCIATED WITH A VARIETY OF ADVERSE HEALTH EFFECTS, INCLUDING LUNG, BLADDER, KIDNEY, AND LIVER CANCER. SEVERAL MECHANISMS HAVE BEEN PROPOSED FOR ARSENIC-INDUCED TUMORIGENESIS; HOWEVER, INSUFFICIENT KNOWLEDGE AND MANY UNANSWERED QUESTIONS REMAIN TO EXPLAIN THE INTEGRATED MOLECULAR PATHOGENESIS OF ARSENIC CARCINOGENICITY. IN THE PRESENT STUDY, USING NON-TUMORIGENIC HUMAN LIVER HEPARG CELLS, WE INVESTIGATED EPIGENETIC ALTERATIONS UPON PROLONGED EXPOSURE TO A NONCYTOTOXIC CONCENTRATION OF SODIUM ARSENITE (NAASO(2)). WE DEMONSTRATE THAT CONTINUOUS EXPOSURE OF HEPARG CELLS TO 1 MICROM SODIUM ARSENITE (NAASO(2)) FOR 14 DAYS RESULTED IN SUBSTANTIAL CYTOSINE DNA DEMETHYLATION AND HYPERMETHYLATION ACROSS THE GENOME, AMONG WHICH THE CLAUDIN 14 (CLDN14) GENE WAS HYPERMETHYLATED AND THE MOST DOWN-REGULATED GENE. ANOTHER IMPORTANT FINDING WAS A PROFOUND LOSS OF HISTONE H3 LYSINE 36 (H3K36) TRIMETHYLATION, WHICH WAS ACCOMPANIED BY INCREASED DAMAGE TO GENOMIC DNA AND AN ELEVATED DE NOVO MUTATION FREQUENCY. THESE RESULTS DEMONSTRATE THAT CONTINUOUS EXPOSURE OF HEPARG CELLS TO A NONCYTOTOXIC CONCENTRATION OF NAASO(2) RESULTS IN SUBSTANTIAL EPIGENETIC ABNORMALITIES ACCOMPANIED BY SEVERAL CARCINOGENESIS-RELATED EVENTS, INCLUDING INDUCTION OF EPITHELIAL-TO-MESENCHYMAL TRANSITION, DAMAGE TO DNA, INHIBITION OF DNA REPAIR GENES, AND INDUCTION OF DE NOVO MUTATIONS. IMPORTANTLY, THIS STUDY HIGHLIGHTS THE INTIMATE MECHANISTIC LINK AND INTERPLAY BETWEEN TWO FUNDAMENTAL CANCER-ASSOCIATED EVENTS, EPIGENETIC AND GENETIC ALTERATIONS, IN ARSENIC-ASSOCIATED CARCINOGENESIS. 2020 7 5949 26 TARGETING THE PRC2-DEPENDENT EPIGENETIC PROGRAM ALLEVIATES URINARY TRACT INFECTIONS. URINARY TRACT INFECTION (UTI) IS A PERVASIVE HEALTH PROBLEM WORLDWIDE. PATIENTS WITH A HISTORY OF UTIS SUFFER INCREASED RISK OF RECURRENT INFECTIONS, A MAJOR RISK OF ANTIBIOTIC RESISTANCE. HERE, WE SHOW THAT BLADDER INFECTIONS INDUCE EXPRESSION OF EZH2 IN BLADDER UROTHELIAL CELLS. EZH2 IS THE METHYLTRANSFERASE OF POLYCOMB REPRESSOR COMPLEX 2 (PRC2)-A POTENT EPIGENETIC REGULATOR. UROTHELIUM-SPECIFIC INACTIVATION OF PRC2 RESULTS IN REDUCED URINE BACTERIAL BURDEN, MUTED INFLAMMATORY RESPONSE, AND DECREASED ACTIVITY OF THE NF-KAPPAB SIGNALING PATHWAY. PRC2 INACTIVATION ALSO FACILITATES PROPER REGENERATION AFTER UROTHELIAL DAMAGE FROM UTIS, BY ATTENUATING BASAL CELL HYPERPLASIA AND INCREASING UROTHELIAL DIFFERENTIATION. IN ADDITION, TREATMENT WITH EZH2-SPECIFIC SMALL-MOLECULE INHIBITORS IMPROVES OUTCOMES OF THE CHRONIC AND SEVERE BLADDER INFECTIONS IN MICE. THESE FINDINGS COLLECTIVELY SUGGEST THAT THE PRC2-DEPENDENT EPIGENETIC REPROGRAMING CONTROLS THE AMPLITUDE OF INFLAMMATION AND SEVERITY OF UTIS AND THAT EZH2 INHIBITORS MAY BE A VIABLE NON-ANTIBIOTIC STRATEGY TO MANAGE CHRONIC AND SEVERE UTIS. 2023 8 3396 23 HOST SHP1 PHOSPHATASE ANTAGONIZES HELICOBACTER PYLORI CAGA AND CAN BE DOWNREGULATED BY EPSTEIN-BARR VIRUS. MOST IF NOT ALL GASTRIC CANCERS ARE ASSOCIATED WITH CHRONIC INFECTION OF THE STOMACH MUCOSA WITH HELICOBACTER PYLORI CAGA-POSITIVE STRAINS(1-4). APPROXIMATELY 10% OF GASTRIC CANCERS ALSO HARBOUR EPSTEIN-BARR VIRUS (EBV) IN THE CANCER CELLS(5,6). FOLLOWING DELIVERY INTO GASTRIC EPITHELIAL CELLS VIA TYPE IV SECRETION(7,8), THE CAGA-ENCODED CAGA PROTEIN UNDERGOES TYROSINE PHOSPHORYLATION ON THE GLU-PRO-ILE-TYR-ALA (EPIYA) MOTIFS INITIALLY BY SRC FAMILY KINASES (SFKS) AND THEN BY C-ABL(9,10). TYROSINE-PHOSPHORYLATED CAGA BINDS TO THE PRO-ONCOGENIC PROTEIN TYROSINE PHOSPHATASE SHP2 AND THEREBY DEREGULATES THE PHOSPHATASE ACTIVITY(11,12), WHICH HAS BEEN CONSIDERED TO PLAY AN IMPORTANT ROLE IN GASTRIC CARCINOGENESIS(13). HERE WE SHOW THAT THE SHP2 HOMOLOGUE SHP1 INTERACTS WITH CAGA INDEPENDENTLY OF THE EPIYA MOTIF. THE INTERACTION POTENTIATES THE PHOSPHATASE ACTIVITY OF SHP1 THAT DAMPENS THE ONCOGENIC ACTION OF CAGA BY DEPHOSPHORYLATING THE CAGA EPIYA MOTIFS. IN VITRO INFECTION OF GASTRIC EPITHELIAL CELLS WITH EBV INDUCES SHP1 PROMOTER HYPERMETHYLATION, WHICH STRENGTHENS PHOSPHORYLATION-DEPENDENT CAGA ACTION VIA EPIGENETIC DOWNREGULATION OF SHP1 EXPRESSION. CLINICAL SPECIMENS OF EBV-POSITIVE GASTRIC CANCERS ALSO EXHIBIT SHP1 HYPERMETHYLATION WITH REDUCED SHP1 EXPRESSION. THE RESULTS REVEAL THAT SHP1 IS THE LONG-SOUGHT PHOSPHATASE THAT CAN ANTAGONIZE CAGA. AUGMENTED H. PYLORI CAGA ACTIVITY, VIA SHP1 INHIBITION, MIGHT ALSO CONTRIBUTE TO THE DEVELOPMENT OF EBV-POSITIVE GASTRIC CANCER. 2016 9 977 43 CHRONIC ORAL EXPOSURE TO INORGANIC ARSENATE INTERFERES WITH METHYLATION STATUS OF P16INK4A AND RASSF1A AND INDUCES LUNG CANCER IN A/J MICE. ALTHOUGH INORGANIC ARSENATE (IAS(V)) OR ARSENITE (IAS(III)) IS CLEARLY A HUMAN CARCINOGEN, IT HAS BEEN DIFFICULT TO PRODUCE TUMORS IN RODENTS. IN THE PRESENT STUDY, WE ORALLY ADMINISTERED IAS(V) TO A/J MICE TO EXAMINE ARSENIC CARCINOGENICITY IN RODENT. A/J MICE (MALE, N = 120) ASSIGNED TO FOUR GROUPS WERE GIVEN DRINKING WATER CONTAINING 0, 1, 10, AND 100 PPM IAS(V) FOR 18 MONTHS. AT THE END OF EXPERIMENT, THE COMPLETE LUNGS WERE REMOVED AND USED FOR EXAMINING HISTOPATHOLOGY AND EXTRACTING RNA AND DNA. EPIGENETIC EFFECTS OF IAS(V) ON DNA METHYLATION PATTERNS OF P16INK4A AND RASSF1A GENES WERE DETERMINED BY METHYLATION-SPECIFIC POLYMERASE CHAIN REACTION. CHANGES OF P16INK4A AND RASSF1A AT MRNA AND PROTEIN LEVELS WERE EXAMINED BY REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION AND IMMUNOHISTOCHEMISTRY. ARSENIC WAS ACCUMULATED DOSE DEPENDENTLY IN THE LUNG TISSUES OF IAS(V)-EXPOSED MICE. INCREASE IN LUNG TUMOR NUMBER AND LUNG TUMOR SIZE WAS OBSERVED IN IAS(V)-EXPOSED MICE COMPARED TO THE CONTROL. HISTOPATHOLOGICAL EXAMINATION SHOWED THAT THE RATE OF POORLY DIFFERENTIATED LUNG ADENOCARCINOMA WAS MUCH HIGHER IN IAS(V)-EXPOSED MICE THAN IN THE CONTROL. METHYLATION RATES APPEARED TO BE HIGHER IN A DOSE-RELATED TENDENCY IN LUNG TUMORS FROM IAS(V)-EXPOSED MICE COMPARED TO THE CONTROL. LOWER OR LOSS OF P16INK4A AND RASSF1A EXPRESSION WAS FOUND IN LUNG TUMORS FROM IAS(V)-EXPOSED MICE, COMPARED TO THAT IN NONTUMOR LUNG TISSUES FROM BOTH CONTROL AND IAS(V)-EXPOSED MICE, AND THIS REDUCED OR LOST EXPRESSION WAS IN ACCORDANCE WITH HYPERMETHYLATION OF THE GENES. IN CONCLUSION, IAS(V) EXPOSURE INCREASED LUNG TUMOR INCIDENCE AND MULTIPLICITY IN A/J MICE. EPIGENETIC CHANGES OF TUMOR SUPPRESSOR GENES SUCH AS P16INK4A AND RASSF1A ARE INVOLVED IN THE IAS(V)-INDUCED LUNG CARCINOGENESIS. 2006 10 3983 43 LONG-TERM EXPOSURE TO CIGARETTE SMOKE EXTRACT INDUCES HYPOMETHYLATION AT THE RUNX3 AND IGF2-H19 LOCI IN IMMORTALIZED HUMAN UROTHELIAL CELLS. CIGARETTE SMOKING IS THE SINGLE MOST IMPORTANT EPIDEMIOLOGICAL RISK FACTOR FOR BLADDER CANCER BUT IT IS NOT KNOWN WHETHER EXPOSURE OF UROTHELIAL CELLS TO THE SYSTEMIC SOLUBLE CONTENTS OF CIGARETTE SMOKE IS DIRECTLY CAUSATIVE TO BLADDER CANCER AND THE ASSOCIATED EPIGENETIC CHANGES SUCH AS TUMOR SUPPRESSOR GENE HYPERMETHYLATION. WE UNDERTOOK THIS STUDY TO INVESTIGATE IF LONG-TERM TREATMENT OF HUMAN UROTHELIAL CELLS WITH CIGARETTE SMOKE EXTRACT (CSE) RESULTS IN TUMOR SUPPRESSOR GENE HYPERMETHYLATION, A PHENOTYPE THAT WAS PREVIOUSLY ASSOCIATED WITH LONG-TERM CONSTANT CSE TREATMENT OF AIRWAY EPITHELIAL CELLS. WE CHRONICALLY TREATED AN IMMORTALIZED HUMAN UROTHELIAL CELL LINE UROTSA WITH CSE USING A CYCLIC DAILY REGIMEN BUT THE CELLS WERE CULTURED IN CSE-FREE MEDIUM BETWEEN DAILY TREATMENTS. BISULFITE SEQUENCING AND REAL-TIME PCR ARRAY-BASED METHYLATION PROFILING WERE EMPLOYED TO EVALUATE METHYLATION CHANGES AT TUMOR SUPPRESSOR GENE LOCI IN THE CHRONICALLY CSE-TREATED CELLS VERSUS THE PASSAGE-MATCHED UNTREATED CONTROL CELLS. THE RUNX3 TUMOR SUPPRESSOR GENE PROMOTER WAS HYPOMETHYLATED WITH A SIGNIFICANT INCREASE IN PROPORTION OF THE COMPLETELY UNMETHYLATED HAPLOTYPE AFTER THE LONG-TERM CSE TREATMENT; WHEREAS RUNX3 PROMOTER HYPERMETHYLATION WAS PREVIOUSLY REPORTED FOR BLADDER CANCERS OF SMOKERS. HYPOMETHYLATION INDUCED BY THE LONG-TERM CSE TREATMENT WAS ALSO OBSERVED FOR THE IGF2-H19 LOCUS. THE METHYLATION STATUS AT THE PRSS8/PROSTASIN AND 16 ADDITIONAL LOCI HOWEVER, WAS UNAFFECTED BY THE CHRONIC CSE TREATMENT. TRANSIENT CSE TREATMENT OVER 1 DAILY REGIMEN RESULTED IN TRANSCRIPTIONAL DOWN-REGULATION OF RUNX3 AND H19, BUT ONLY THE H19 TRANSCRIPTION WAS DOWN-REGULATED IN THE CHRONICALLY CSE-TREATED UROTHELIAL CELLS. TRANSCRIPTION OF A KEY ENZYME IN ONE-CARBON METABOLISM, DIHYDROFOLATE REDUCTASE (DHFR) WAS GREATLY REDUCED BY THE LONG-TERM CSE TREATMENT, POTENTIALLY SERVING AS A MECHANISM FOR THE HYPOMETHYLATION PHENOTYPE VIA A REDUCED SUPPLY OF METHYL DONOR. IN CONCLUSION, CHRONIC CYCLIC CSE TREATMENT OF UROTHELIAL CELLS INDUCED HYPOMETHYLATION RATHER THAN HYPERMETHYLATION AT SPECIFIC LOCI. 2013 11 4267 34 MICROARRAY DATASET OF TRANSIENT AND PERMANENT DNA METHYLATION CHANGES IN HELA CELLS UNDERGOING INORGANIC ARSENIC-MEDIATED EPITHELIAL-TO-MESENCHYMAL TRANSITION. THE NOVEL DATASET PRESENTED HERE REPRESENTS THE RESULTS OF THE CHANGING PATTERN OF DNA METHYLATION PROFILES IN HELA CELLS EXPOSED TO CHRONIC LOW DOSE (0.5 MICROM) SODIUM ARSENITE, RESULTING IN EPITHELIAL-TO-MESENCHYMAL TRANSITION, AS WELL AS DNA METHYLATION PATTERNS IN CELLS WHERE INORGANIC ARSENIC HAS BEEN REMOVED. INORGANIC ARSENIC IS A KNOWN CARCINOGEN, THOUGH NOT MUTAGENIC. SEVERAL MECHANISMS HAVE BEEN PROPOSED AS TO HOW INORGANIC ARSENIC DRIVES CARCINOGENESIS SUCH AS REGULATION OF THE CELL?S REDOX POTENTIAL AND/OR EPIGENETICS. IN FACT, THERE ARE GENE SPECIFIC STUDIES AND LIMITED GENOME-WIDE STUDIES THAT HAVE IMPLICATED EPIGENETIC FACTORS SUCH AS DNA METHYLATION IN INORGANIC ARSENIC-MEDIATED EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT). HOWEVER, GENOME-WIDE STUDIES ABOUT THE IMPACT OF 1) CHRONIC, LOW-DOSE INORGANIC ARSENIC EXPOSURE ON DNA METHYLATION PATTERNS DURING INORGANIC ARSENIC-INDUCED EPITHELIAL-TO-MESENCHYMAL TRANSITION, AND 2) THE REMOVAL INORGANIC ARSENIC (REVERSAL) ON DNA METHYLATION PATTERNS, IS LACKING. FOR THIS DATASET, TWO REPLICATES WERE PERFORMED WITH EACH OF THE SAMPLES - NON-TREATED, INORGANIC ARSENIC-TREATED, AND REVERSE-TREATED CELLS. WE PROVIDE NORMALIZED AND PROCESSED DATA, AND LOG2 FOLD CHANGE IN DNA METHYLATION. THE RAW MICROARRAY DATA ARE AVAILABLE THROUGH NCBI GEO, ACCESSION NUMBER GSE95232 AND A RELATED RESEARCH PAPER HAS BEEN ACCEPTED FOR PUBLISHED IN TOXICOLOGY AND APPLIED PHARMACOLOGY (ECKSTEIN ET AL., 2017) [1]. 2017 12 6562 39 TRANSIENT AND PERMANENT CHANGES IN DNA METHYLATION PATTERNS IN INORGANIC ARSENIC-MEDIATED EPITHELIAL-TO-MESENCHYMAL TRANSITION. CHRONIC LOW DOSE INORGANIC ARSENIC EXPOSURE CAUSES CELLS TO TAKE ON AN EPITHELIAL-TO-MESENCHYMAL PHENOTYPE, WHICH IS A CRUCIAL PROCESS IN CARCINOGENESIS. INORGANIC ARSENIC IS NOT A MUTAGEN AND THUS EPIGENETIC ALTERATIONS HAVE BEEN IMPLICATED IN THIS PROCESS. INDEED, DURING THE EPITHELIAL-TO-MESENCHYMAL TRANSITION, MORPHOLOGIC CHANGES TO CELLS CORRELATE WITH CHANGES IN CHROMATIN STRUCTURE AND GENE EXPRESSION, ULTIMATELY DRIVING THIS PROCESS. HOWEVER, STUDIES ON THE EFFECTS OF INORGANIC ARSENIC EXPOSURE/WITHDRAWAL ON THE EPITHELIAL-TO-MESENCHYMAL TRANSITION AND THE IMPACT OF EPIGENETIC ALTERATIONS IN THIS PROCESS ARE LIMITED. IN THIS STUDY WE USED HIGH-RESOLUTION MICROARRAY ANALYSIS TO MEASURE THE CHANGES IN DNA METHYLATION IN CELLS UNDERGOING INORGANIC ARSENIC-INDUCED EPITHELIAL-TO-MESENCHYMAL TRANSITION, AND ON THE REVERSAL OF THIS PROCESS, AFTER REMOVAL OF THE INORGANIC ARSENIC EXPOSURE. WE FOUND THAT CELLS EXPOSED TO CHRONIC, LOW-DOSE INORGANIC ARSENIC EXPOSURE SHOWED 30,530 SITES WERE DIFFERENTIALLY METHYLATED, AND WITH INORGANIC ARSENIC WITHDRAWAL SEVERAL DIFFERENTIAL METHYLATED SITES WERE REVERSED, ALBEIT NOT COMPLETELY. FURTHERMORE, THESE CHANGES IN DNA METHYLATION MAINLY CORRELATED WITH CHANGES IN GENE EXPRESSION AT MOST SITES TESTED BUT NOT AT ALL. THIS STUDY SUGGESTS THAT DNA METHYLATION CHANGES ON GENE EXPRESSION ARE NOT CLEAR-CUT AND PROVIDE A PLATFORM TO BEGIN TO UNCOVER THE RELATIONSHIP BETWEEN DNA METHYLATION AND GENE EXPRESSION, SPECIFICALLY WITHIN THE CONTEXT OF INORGANIC ARSENIC TREATMENT. 2017 13 1987 34 EPIGENETIC ALTERATIONS OF CXCL5 IN CR(VI)-INDUCED CARCINOGENESIS. CHRONIC EXPOSURE TO HEXAVALENT CHROMIUM COMPOUNDS [CR(VI)] IS ASSOCIATED WITH AN INCREASED RISK OF CANCERS, BUT THE MOLECULAR MECHANISMS REMAIN TO BE ELUCIDATED. IN THIS STUDY, WE FOUND THAT CXCL5 LEVELS IN PERIPHERAL BLOOD MONOCYTES (PBMCS) AND PLASMA FROM WORKERS WITH OCCUPATIONAL EXPOSURE TO CR(VI) WERE DRAMATICALLY UPREGULATED COMPARED TO NON-EXPOSURE HEALTHY SUBJECTS, AND PLASMA C-X-C MOTIF CHEMOKINE LIGAND 5 (CXCL5) CXCL5 LEVELS WERE POSITIVELY CORRELATED WITH CR CONCENTRATIONS IN SUBJECTS' TOENAILS. ZINC CHROMATE EXPOSED MICE SHOWED HIGHER LEVELS OF CXCL5 AND ITS RECEPTOR CXCR2 IN LUNG TISSUES, AND IN PBMCS. SIMILAR CXCL5 UPREGULATION WAS EVIDENT IN CR(VI)-INDUCED TRANSFORMED (CR-T) CELLS WITH LONG-TERM CR(VI) TREATMENT. MECHANISTIC STUDIES SHOWED THAT ELEVATED CXCL5 EXPRESSION LEVELS WERE REGULATED BY CR(VI)-INDUCED HISTONE MODIFICATIONS AND DNA HYPOMETHYLATION, AND THAT THE C-MYC/P300 COMPLEX WAS A KEY UPSTREAM REGULATOR OF HISTONE H3 ACETYLATION. CXCL5 OVEREXPRESSION PROMOTED CR(VI)-INDUCED THE EPITHELIAL TO MESENCHYME TRANSITION (EMT) BY UPREGULATING ZINC FINGER E-BOX BINDING HOMEOBOX 1 (ZEB1) TO PROMOTE TUMOR DEVELOPMENT. OUR FINDINGS IDENTIFY A NOVEL MECHANISM BY WHICH CXCL5 IS UPREGULATED AND PROMOTES EMT AND CARCINOGENESIS UPON CHRONIC CR(VI) EXPOSURE. OUR WORK ALSO IMPLIES THAT CXCL5 MRNA AND PROTEIN LEVELS WILL ELEVATE IN PBMCS AND SERUM AFTER OCCUPATIONAL CR(VI) EXPOSURE, WHICH MAY BE A POTENTIAL TARGET AND BIOMARKER FOR CANCER PREVENTION AND HEALTH SURVEILLANCE AMONG POPULATIONS EXPOSED TO CR(VI). 2022 14 5492 26 REVIEW OF ARSENIC TOXICITY, SPECIATION AND POLYADENYLATION OF CANONICAL HISTONES. ARSENIC CONTAMINATION IMPACTS HUNDREDS OF MILLIONS OF PEOPLE IN THE WORLD. ARSENIC IS A WELL-ESTABLISHED HUMAN CARCINOGEN AND HAS BEEN SHOWN TO CAUSE SKIN, LUNG, BLADDER, LIVER, PROSTATE AND KIDNEY CANCERS, IN HUMANS. MECHANISMS THAT UNDERLIE ARSENIC-MEDIATED CARCINOGENESIS, INCLUDING EPIGENETIC ALTERATIONS, REMAIN LARGELY UNKNOWN. HUMAN EXPOSURE TO ARSENIC IS REVIEWED, AND THE MECHANISMS OF ITS ACUTE AND CHRONIC TOXICITY AND MECHANISMS OF ITS CARCINOGENESIS IN HUMANS ARE DISCUSSED. ARSENIC IS ONE OF THE FEW METALS THAT IS METABOLIZED IN VIVO, AND ARSENIC METHYLATION AND HOW THIS RESULTS IN A SHORTER HALF-LIFE IN VIVO ARE DISCUSSED. A REVIEW OF RECENT FINDINGS THAT ARSENIC CAUSES LOSS IN THE CELLULAR LEVELS OF STEM LOOP BINDING PROTEIN (SLBP) RESULTING IN POLYADENYLATION OF CANONICAL HISTONES (H3.1) AS A DEFAULT, INCREASING LEVELS OF H3.1 PROTEIN OUTSIDE OF S-PHASE. MALIGNANT CELL TRANSFORMATION IS INDUCED BY KNOCKDOWN OF SLBP AND BY OVEREXPRESSION OF POLYADENYLATED H3.1. ARSENIC INDUCED POLYADENYLATION OF H3.1 CAUSES ENHANCED LEVELS OF H3.1 PROTEIN DISPLACING H3.3 PROTEIN FROM ITS CELLULAR BINDING SITES, SINCE THE TWO PROTEINS DIFFER BY ONLY 5 AMINO ACIDS. KNOCKDOWN OF H3.3 ALONE CAN INDUCE CARCINOGENESIS, AND THEREFORE DISPLACEMENT OF FUNCTIONAL H3.3 PROTEIN BY INCREASED H3.1 PROTEIN, IS LIKELY A MECHANISM OF ARSENIC CARCINOGENESIS. 2019 15 6614 33 ULTRAVIOLET IRRADIATION INDUCES KERATINOCYTE PROLIFERATION AND EPIDERMAL HYPERPLASIA THROUGH THE ACTIVATION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR. CHRONIC EXPOSURE TO ULTRAVIOLET (UV) IRRADIATION INDUCES SKIN CANCER, IN PART, THROUGH EPIGENETIC MECHANISMS THAT RESULT IN THE DEREGULATION OF CELL PROLIFERATION. UV IRRADIATION ALSO RAPIDLY ACTIVATES THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR). SINCE EGFR ACTIVATION IS STRONGLY MITOGENIC IN MANY CELL TYPES INCLUDING KERATINOCYTES OF THE SKIN, WE HYPOTHESIZED THAT UV-INDUCED CUTANEOUS PROLIFERATION RESULTS FROM EGFR ACTIVATION. THE ROLE OF EGFR ACTIVATION IN THE RESPONSE OF THE SKIN TO UV WAS DETERMINED USING EGFR-NULL AND EGFR-WILD-TYPE SKIN GRAFTED ONTO ATHYMIC NUDE MOUSE HOSTS, BECAUSE EGFR-NULL MICE SURVIVE ONLY A FEW DAYS AFTER BIRTH. EGFR WAS RAPIDLY ACTIVATED IN MOUSE EPIDERMIS FOLLOWING EXPOSURE TO UV, AS DETECTED BY THE PHOSPHORYLATION OF EGFR ON TYROSINE RESIDUES 992, 1045, 1068 AND 1173. UV INDUCED EPIDERMAL HYPERPLASIA IN EGFR-WILD-TYPE SKIN BETWEEN 48 AND 72 H POST-UV. HOWEVER, NO EPIDERMAL HYPERPLASIA OCCURRED IN EGFR-NULL SKIN. BASELINE CELL PROLIFERATION WAS SIMILAR IN SKIN GRAFTS OF BOTH GENOTYPES. HOWEVER, UV EXPOSURE INCREASED CELL PROLIFERATION, AS MEASURED BY KI67 IMMUNOHISTOCHEMISTRY AND PROLIFERATING CELL NUCLEAR ANTIGEN IMMUNOBLOTTING, MAXIMALLY AT 48 H TO A LEVEL MORE THAN THREE TIMES HIGHER IN WILD-TYPE COMPARED WITH EGFR-NULL SKIN. APOPTOTIC CELL DEATH, AS MEASURED BY TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE BIOTIN-DUTP NICK END LABELING (TUNEL) ANALYSIS, WAS ALSO INCREASED IN UV-EXPOSED EGFR-NULL SKIN WHEN COMPARED WITH WILD-TYPE 1-2 DAYS POST-UV. THESE CHANGES IN CELLULAR HOMEOSTASIS AFTER UV WERE ACCOMPANIED BY INCREASED CYCLIN D EXPRESSION IN WILD-TYPE BUT NOT EGFR-NULL SKIN AND INCREASED EXPRESSION OF P53 AND THE CYCLIN-DEPENDENT KINASE (CDK) INHIBITOR P21WAF1 IN EGFR-NULL SKIN WHEN COMPARED WITH WILD-TYPE. COLLECTIVELY, THESE RESULTS DEMONSTRATE THAT THE UV-INDUCED ACTIVATION OF EGFR AUGMENTS KERATINOCYTE PROLIFERATION AND SUPPRESSES APOPTOSIS, LEADING TO EPIDERMAL HYPERPLASIA, ASSOCIATED WITH INCREASED G1 CYCLIN EXPRESSION AND SUPPRESSION OF CDK INHIBITOR EXPRESSION. 2006 16 2961 39 GENETIC AND EPIGENETIC MECHANISMS IN METAL CARCINOGENESIS AND COCARCINOGENESIS: NICKEL, ARSENIC, AND CHROMIUM. CHRONIC EXPOSURE TO NICKEL(II), CHROMIUM(VI), OR INORGANIC ARSENIC (IAS) HAS LONG BEEN KNOWN TO INCREASE CANCER INCIDENCE AMONG AFFECTED INDIVIDUALS. RECENT EPIDEMIOLOGICAL STUDIES HAVE FOUND THAT CARCINOGENIC RISKS ASSOCIATED WITH CHROMATE AND IAS EXPOSURES WERE SUBSTANTIALLY HIGHER THAN PREVIOUSLY THOUGHT, WHICH LED TO MAJOR REVISIONS OF THE FEDERAL STANDARDS REGULATING AMBIENT AND DRINKING WATER LEVELS. GENOTOXIC EFFECTS OF CR(VI) AND IAS ARE STRONGLY INFLUENCED BY THEIR INTRACELLULAR METABOLISM, WHICH CREATES SEVERAL REACTIVE INTERMEDIATES AND BYPRODUCTS. TOXIC METALS ARE CAPABLE OF POTENT AND SURPRISINGLY SELECTIVE ACTIVATION OF STRESS-SIGNALING PATHWAYS, WHICH ARE KNOWN TO CONTRIBUTE TO THE DEVELOPMENT OF HUMAN CANCERS. DEPENDING ON THE METAL, ASCORBATE (VITAMIN C) HAS BEEN FOUND TO ACT EITHER AS A STRONG ENHANCER OR SUPPRESSOR OF TOXIC RESPONSES IN HUMAN CELLS. IN ADDITION TO GENETIC DAMAGE VIA BOTH OXIDATIVE AND NONOXIDATIVE (DNA ADDUCTS) MECHANISMS, METALS CAN ALSO CAUSE SIGNIFICANT CHANGES IN DNA METHYLATION AND HISTONE MODIFICATIONS, LEADING TO EPIGENETIC SILENCING OR REACTIVATION OF GENE EXPRESSION. IN VITRO GENOTOXICITY EXPERIMENTS AND RECENT ANIMAL CARCINOGENICITY STUDIES PROVIDED STRONG SUPPORT FOR THE IDEA THAT METALS CAN ACT AS COCARCINOGENS IN COMBINATION WITH NONMETAL CARCINOGENS. COCARCINOGENIC AND COMUTAGENIC EFFECTS OF METALS ARE LIKELY TO STEM FROM THEIR ABILITY TO INTERFERE WITH DNA REPAIR PROCESSES. OVERALL, METAL CARCINOGENESIS APPEARS TO REQUIRE THE FORMATION OF SPECIFIC METAL COMPLEXES, CHROMOSOMAL DAMAGE, AND ACTIVATION OF SIGNAL TRANSDUCTION PATHWAYS PROMOTING SURVIVAL AND EXPANSION OF GENETICALLY/EPIGENETICALLY ALTERED CELLS. 2008 17 975 40 CHRONIC OCCUPATIONAL EXPOSURE TO ARSENIC INDUCES CARCINOGENIC GENE SIGNALING NETWORKS AND NEOPLASTIC TRANSFORMATION IN HUMAN LUNG EPITHELIAL CELLS. CHRONIC ARSENIC EXPOSURE REMAINS A HUMAN HEALTH RISK; HOWEVER A CLEAR MODE OF ACTION TO UNDERSTAND GENE SIGNALING-DRIVEN ARSENIC CARCINOGENESIS IS CURRENTLY LACKING. THIS STUDY CHRONICALLY EXPOSED HUMAN LUNG EPITHELIAL BEAS-2B CELLS TO LOW-DOSE ARSENIC TRIOXIDE TO ELUCIDATE CANCER PROMOTING GENE SIGNALING NETWORKS ASSOCIATED WITH ARSENIC-TRANSFORMED (B-AS) CELLS. FOLLOWING A 6MONTH EXPOSURE, EXPOSED CELLS WERE ASSESSED FOR ENHANCED CELL PROLIFERATION, COLONY FORMATION, INVASION ABILITY AND IN VIVO TUMOR FORMATION COMPARED TO CONTROL CELL LINES. COLLECTED MRNA WAS SUBJECTED TO WHOLE GENOME EXPRESSION MICROARRAY PROFILING FOLLOWED BY IN SILICO INGENUITY PATHWAY ANALYSIS (IPA) TO IDENTIFY LUNG CARCINOGENESIS MODES OF ACTION. B-AS CELLS DISPLAYED SIGNIFICANT INCREASES IN PROLIFERATION, COLONY FORMATION AND INVASION ABILITY COMPARED TO BEAS-2B CELLS. B-AS INJECTIONS INTO NUDE MICE RESULTED IN DEVELOPMENT OF PRIMARY AND SECONDARY METASTATIC TUMORS. ARSENIC EXPOSURE RESULTED IN WIDESPREAD UP-REGULATION OF GENES ASSOCIATED WITH MITOCHONDRIAL METABOLISM AND INCREASED REACTIVE OXYGEN SPECIES PROTECTION SUGGESTING MITOCHONDRIAL DYSFUNCTION. CARCINOGENIC INITIATION VIA REACTIVE OXYGEN SPECIES AND EPIGENETIC MECHANISMS WAS FURTHER SUPPORTED BY ALTERED DNA REPAIR, HISTONE, AND ROS-SENSITIVE SIGNALING. NF-KAPPAB, MAPK AND NCOR1 SIGNALING DISRUPTED PPARALPHA/DELTA-MEDIATED LIPID HOMEOSTASIS. A 'PRO-CANCER' GENE SIGNALING NETWORK IDENTIFIED INCREASED SURVIVAL, PROLIFERATION, INFLAMMATION, METABOLISM, ANTI-APOPTOSIS AND MOBILITY SIGNALING. IPA-RANKED SIGNALING NETWORKS IDENTIFIED ALTERED P21, EF1ALPHA, AKT, MAPK, AND NF-KAPPAB SIGNALING NETWORKS PROMOTING GENETIC DISORDER, ALTERED CELL CYCLE, CANCER AND CHANGES IN NUCLEIC ACID AND ENERGY METABOLISM. IN CONCLUSION, TRANSFORMED B-AS CELLS WITH THEIR WHOLE GENOME EXPRESSION PROFILE PROVIDE AN IN VITRO ARSENIC MODEL FOR FUTURE LUNG CANCER SIGNALING RESEARCH AND DATA FOR CHRONIC ARSENIC EXPOSURE RISK ASSESSMENT. 2012 18 6078 40 THE EFFECT OF CHRONIC ARSENIC EXPOSURE IN ZEBRAFISH. ARSENIC IS A PREVALENT ENVIRONMENTAL TOXIN AND A GROUP ONE HUMAN CARCINOGENIC AGENT. CHRONIC ARSENIC EXPOSURE HAS BEEN ASSOCIATED WITH MANY HUMAN DISEASES. THE AIM OF THIS STUDY IS TO EVALUATE ZEBRAFISH AS AN ANIMAL MODEL TO ASSESS ARSENIC TOXICITY IN ELEVATED LONG-TERM ARSENIC EXPOSURE. WITH PROLONGED EXPOSURE (6 MONTHS) TO VARIOUS CONCENTRATIONS OF ARSENIC FROM 50 PPB TO 300 PPB, EFFECTS OF ARSENIC ACCUMULATION IN ZEBRAFISH TISSUES, AND PHENOTYPES WERE INVESTIGATED. RESULTS SHOWED THAT THERE ARE NO SIGNIFICANT CHANGES OF ARSENIC RETENTION IN ZEBRAFISH TISSUES, AND ZEBRAFISH DID NOT EXHIBIT ANY VISIBLE TUMOR FORMATION UNDER ARSENIC EXPOSURE CONDITIONS. HOWEVER, THE ZEBRAFISH DEMONSTRATE A DYSFUNCTION IN THEIR NEUROLOGICAL SYSTEM, WHICH IS REFLECTED BY A REDUCTION OF LOCOMOTIVE ACTIVITY. MOREOVER, ELEVATED LEVELS OF THE SUPEROXIDE DISMUTASE (SOD2) PROTEIN WERE DETECTED IN THE EYE AND LIVER, SUGGESTING INCREASED OXIDATIVE STRESS. IN ADDITION, THE PROGENIES OF ARSENIC-TREATED PARENTS DISPLAYED A SMALLER BIOMASS (FOUR-FOLD REDUCTION IN BODY WEIGHT) COMPARED WITH THOSE FROM THEIR PARENTAL CONTROLS. THIS RESULT INDICATES THAT ARSENIC MAY INDUCE GENETIC OR EPIGENETIC CHANGES THAT ARE THEN PASSED ON TO THE NEXT GENERATION. OVERALL, THIS STUDY DEMONSTRATES THAT ZEBRAFISH IS A CONVENIENT VERTEBRATE MODEL WITH ADVANTAGES IN THE EVALUATION OF ARSENIC-ASSOCIATED NEUROLOGICAL DISORDERS AS WELL AS ITS INFLUENCES ON THE OFFSPRING. 2016 19 3636 27 INCREASED DNA METHYLTRANSFERASE ACTIVITY AND DNA METHYLATION FOLLOWING EPIDERMAL GROWTH FACTOR STIMULATION IN OVARIAN CANCER CELLS. OVARIAN CANCER PROGRESSION IS CORRELATED WITH ACCUMULATION OF ABERRANT CPG ISLAND METHYLATION. IN OVARIAN CANCER, ASCITES FLUID CONTAINS NUMEROUS EPIDERMAL-GROWTH-FACTOR-RECEPTOR (EGFR) ACTIVATORS, WHICH COULD RESULT IN A TUMOR MICROENVIRONMENT OF CONSTANT EGFR ACTIVATION. SIGNALING PATHWAYS DOWNSTREAM OF EGFR, SUCH AS RAS, REGULATE DNA METHYLATION. WE HYPOTHESIZED THAT CHRONIC EGFR ACTIVATION COULD ALTER DNA METHYLATION. WE FOUND THAT EGFR ACTIVATION INCREASED DNA METHYLTRANSFERASE (DNMT) ACTIVITY ACUTELY, AS WELL AS AFTER LONG-TERM EGF TREATMENT OR EXPRESSION OF A MUTATIONALLY ACTIVATED EGFR. FURTHERMORE, THIS INCREASE IN DNMT ACTIVITY WAS DEPENDENT ON EGFR CATALYTIC ACTIVITY AND RESULTED IN INCREASED GLOBAL DNA METHYLATION. ADDITIONALLY, TREATMENT WITH THE DNMT INHIBITOR/HYPOMETHYLATING AGENT 5-AZA-2'-DEOXYCYTIDINE (AZA) INHIBITED THE EGF INDUCED INCREASE OF BOTH DNMT ACTIVITY AND GLOBAL METHYLATION. THESE DATA SUPPORT A ROLE FOR EGFR IN THE PROCESS OF ACCUMULATED DNA METHYLATION DURING OVARIAN CANCER PROGRESSION AND SUGGEST THAT EPIGENETIC THERAPY MAY BE BENEFICIAL FOR THE TREATMENT OF OVARIAN CANCER. 2012 20 2947 40 GENETIC AND EPIGENETIC CHANGES INDUCED BY CHRONIC LOW DOSE EXPOSURE TO ARSENIC OF MOUSE TESTICULAR LEYDIG CELLS. ARSENIC IS AN IMPORTANT ENVIRONMENTAL CARCINOGEN THAT AFFECTS MILLIONS OF PEOPLE WORLDWIDE THROUGH CONTAMINATED WATER SUPPLIES. GENOTOXICITY OF ARSENIC HAS BEEN A TOPIC OF CONTROVERSY. BOTH GENETIC ALTERATIONS (MUTATIONS) AND EPIGENETIC CHANGES (METHYLATION) HAVE BEEN SHOWN TO PLAY A CRUCIAL ROLE IN ENVIRONMENTAL CARCINOGENESIS. CHRONIC EXPOSURE TO ARSENIC HAS BEEN SHOWN TO INDUCE MALIGNANT TRANSFORMATION OF MAMMALIAN CELLS. HOWEVER, THE GENETIC ABERRATIONS INDUCED BY ARSENIC IN THIS PROCESS ARE UNCLEAR. THE PURPOSE OF THIS STUDY WAS TO DETERMINE IF BOTH LOWER (1 PG/ML) AND HIGHER CONCENTRATIONS (100 NG/ML) OF ARSENIC INDUCES EITHER MUTATIONS OR METHYLATION CHANGES THAT COULD LEAD TO THE DEVELOPMENT OF GENOMIC INSTABILITY IN TM3 CELLS, IMMORTALIZED LEYDIG CELLS DERIVED FROM NORMAL MOUSE TESTIS. TWO INDEPENDENT EXPOSURE TIMES WERE USED IN THIS STUDY WHICH RESULTED IN CELLS OF 33 AND 100 GENERATIONS IN AGE. ARSENIC-INDUCED GENETIC AND EPIGENETIC CHANGES WERE SCREENED AT A GENOME-WIDE LEVEL BY RANDOM AMPLIFIED POLYMORPHIC DNA (RAPD), ALSO KNOWN AS AP-PCR METHOD WITH UNDIGESTED DNA AS WELL AS DNA DIGESTED BY THE METHYLATION SENSITIVE ISOSIZOMERIC RESTRICTION ENZYMES MSPI AND HPAII AND UNTREATED CONTROLS. CHANGES IN THE DNA FINGERPRINT OF BOTH, THE RESTRICTION ENZYME DIGESTED DNA (INDICATING METHYLATION CHANGES) AS WELL AS UNDIGESTED DNA (INDICATING MUTATIONS) FROM ARSENIC-TREATED (LOW AS WELL AS HIGH DOSE) SAMPLES WERE OBSERVED AS COMPARED TO THEIR CONTROLS. THUS, THIS STUDY PROVIDES THE FIRST EVIDENCE AT DNA SEQUENCE LEVEL FOR MUTAGENIC POTENTIAL OF ARSENIC. FURTHER CHARACTERIZATION OF THESE ALTERED GENOMIC REGIONS IS UNDERWAY. THE UNDERSTANDING OF THESE GENETIC AND EPIGENETIC CHANGES IN ARSENIC-INDUCED CARCINOGENESIS WILL PROVIDE A BASIS FOR BETTER INTERVENTIONAL APPROACHES IN BOTH THE TREATMENT AND PREVENTION OF ARSENIC-INDUCED CANCER. 2007